Opdivo — Total Revenues
Bristol-Myers Squibb Opdivo — Total Revenues decreased by 1.1% to $2.53B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 7.3%, from $2.36B to $2.53B. Over 3 years (FY 2021 to FY 2024), Opdivo — Total Revenues shows an upward trend with a 7.3% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
An increase indicates strong market demand, successful label expansions, or effective competitive positioning, while a decrease may signal patent expirations, increased competition from biosimilars or new therapies, or shifts in clinical treatment guidelines.
Detailed definition
This metric represents the total global net sales generated from the commercialization of the PD-1 inhibitor therapy Opd...
Peer comparison
Comparable to revenue metrics for flagship oncology blockbusters or key specialty pharmaceutical assets at peer biopharmaceutical companies.
bmy_segment_opdivo_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $1.91B | $1.91B | $1.99B | $1.92B | $2.06B | $2.05B | $2.22B | $2.20B | $2.15B | $2.28B | $2.39B | $2.08B | $2.39B | $2.36B | $2.48B | $2.27B | $2.56B | $2.53B |
| QoQ Change | — | -0.3% | +4.4% | -3.3% | +7.3% | -0.8% | +8.3% | -0.6% | -2.6% | +6.1% | +4.9% | -12.9% | +14.9% | -1.1% | +5.0% | -8.6% | +13.0% | -1.1% |
| YoY Change | — | — | — | — | +8.0% | +7.5% | +11.5% | +14.5% | +4.0% | +11.1% | +7.7% | -5.6% | +11.3% | +3.7% | +3.9% | +9.0% | +7.2% | +7.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Bristol-Myers Squibb's opdivo — total revenues?
- Bristol-Myers Squibb (BMY) reported opdivo — total revenues of $2.53B in Q3 2025.
- How has Bristol-Myers Squibb's opdivo — total revenues changed year-over-year?
- Bristol-Myers Squibb's opdivo — total revenues increased by 7.3% year-over-year, from $2.36B to $2.53B.
- What is the long-term trend for Bristol-Myers Squibb's opdivo — total revenues?
- Over 3 years (2021 to 2024), Bristol-Myers Squibb's opdivo — total revenues has grown at a 7.3% compound annual growth rate (CAGR), from $7.52B to $9.30B.
- What does opdivo — total revenues mean?
- The total revenue generated from the sales of the oncology drug Opdivo.